ClinicalTrials.gg
CompletedNCT01701362Updated Jan 28, 2021Results posted

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

A Phase 3 interventional study of pregabalin and placebo in Neuropathic Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 156 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
Largest of 50
542 · median 109
Started
2012
with 2 others
Phase 3
18 of 50
1 open now
Registered
28th of 50
by date
Lead sponsor
12 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing pregabalin in Neuralgia, this one has the largest enrollment, is one of 3 that started in 2012, is one of 18 in phase 3, and was the 28th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.

03

Conditions studied

  • Neuropathic Pain

Browse trials for

Keywords

  • post-traumatic peripheral neuropathic pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have chronic peripheral neuropathic pain present for than 6 months after a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.
  • Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone in order to complete the IVRS assessments each day, perform telephone visits and complete all required assessments/forms.
  • Subjects must have sufficient post-traumatic neuropathic pain at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Subjects with neuropathic pain due to diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), , trigeminal neuralgia (TGN), carpal tunnel syndrome (CTS) or with central neuropathic pain (for example, due to spinal cord injury) or with Complex Regional Pain Syndrome (CRPS, Type I or Type II).
  • Subjects with other pain that may confound assessment or self-evaluation of the peripheral neuropathic pain.
  • Subjects who have failed pregabalin treatment due to lack of efficacy with an adequate course of therapy at doses greater than or equal to 150 mg/day, who have previously participated in a pregabalin clinical trial or who have been treated with pregabalin at any time during the 6 month period prior to screening.
  • Subjects with epilepsy; pernicious anemia; hematological illnesses; known HIV infection; any clinically unstable cardiovascular (including a myocardial infarction [heart attack] in the 3 months prior to screening), hematological, , endocrine, renal, hepatic (including chronic , hepatitis B within the 3 months prior to screening) respiratory, or gastrointestinal disease; symptomatic peripheral vascular disease including intermittent claudication; uncontrolled diabetes mellitus; untreated hypothyroidism.
  • Subjects with a diagnosis of TR Axis I disorder (including, for example, schizophrenia, bipolar disorder) with the exceptions of Generalized Anxiety Disorder (GAD) or major depression that is clinically stable.
  • Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment.
  • Use of prohibited medications in the absence of appropriate .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
542 participants (actual)

Study arms

  • Active comparator
    pregabalin

    Drug: pregabalin

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization

    Also known as: Lyrica, PD-144723

  • Drugplacebo

    capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization

06

What researchers measure

Primary outcomes

  1. Baseline Mean Pain Score

    This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

    Time frame: Baseline

  2. Change From Baseline to Week 15 in Weekly Mean Pain Score

    This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

    Time frame: up to Week 15

Secondary outcomes

  1. Patient Global Impression of Change (PGIC) at Week 15

    A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale.

    Time frame: Week 15

  2. Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS)

    This is an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context. Note: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7\*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings. "Overall" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks.

    Time frame: up to Week 15

  3. Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])

    A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome.

    Time frame: Week 15

  4. Change From Baseline in Pain Interference Index (BPI-sf)

    BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. It consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes). The BPI-sf pain interference index was calculated as average of the seven individual pain interference scores.

    Time frame: Week 15

  5. Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores

    A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale.

    Time frame: Week 15

  6. Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.

    MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.

    Time frame: Baseline

  7. Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.

    MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.

    Time frame: Week 15

  8. Percentage of Participants in MOS-SS With Optimal Sleep Status.

    MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable.

    Time frame: Week 15

  9. Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%.

    Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.

    Time frame: Week 15

  10. Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50%

    Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.

    Time frame: Week 15

07

Results

Posted Jun 7, 2017

Participant flow

A total of 187 centers participated in the study in 14 countries. During screening, with the exception of daily pain score data that was collected to determine participants eligibility, no participants were treated with active drug and no efficacy data were collected. Only safety and no efficacy data was collected during the taper period.

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started275267
Treated274265
Completed233211
Not completed4256
Withdrew: Adverse events not related to study drug16
Withdrew: Adverse events related to study drug1210
Withdrew: Protocol violation53
Withdrew: No longer willing to participate814
Withdrew: Lost to follow-up69
Withdrew: Insufficient clinical response66
Withdrew: Death01
Withdrew: Randomized but not treated12
Withdrew: Reasons other than those mentioned above35

Outcome measures

PrimaryBaseline Mean Pain Score

This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Baseline Mean Pain Score
units on a scalePregabalinPlacebo
Baseline Mean Pain Score6.41 ± 1.306.54 ± 1.30
PrimaryChange From Baseline to Week 15 in Weekly Mean Pain Score

This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

Time frame:
up to Week 15
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 15 in Weekly Mean Pain Score
units on a scalePregabalinPlacebo
Change From Baseline to Week 15 in Weekly Mean Pain Score-2.12 ± 0.15-1.90 ± 0.16
Statistical analysis
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.1823 · Least squares mean difference: -0.22 · 95% CI -0.54 to 0.10MMRM analysis includes fixed categorical effects of treatment, country, trauma type, visit week, treatment-by-visit interaction, and fixed continuous effect of baseline value. Missing mean pain scores imputed by multiple imputation method
SecondaryPatient Global Impression of Change (PGIC) at Week 15

A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale.

Time frame:
Week 15
Reported as:
Number · Participants
Patient Global Impression of Change (PGIC) at Week 15
ParticipantsPregabalinPlacebo
Very much improved5241
Much improved10579
Minimally improved6162
No change3451
Minimally worse59
Much worse04
Very much worse10
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.0012 (The p-value is derived from CMH test, stratified for pooled center and trauma type and excludes missing values.)
SecondaryChange From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS)

This is an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context. Note: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7\*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings. "Overall" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks.

Time frame:
up to Week 15
Reported as:
Mean · units on a scale
Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS)
units on a scalePregabalinPlacebo
Baseline (raw scores) (N = 274, 265)4.97 ± 2.304.99 ± 2.27
Week 1 (N = 260, 258)-0.66 ± 1.10-0.28 ± 0.91
Week 2 (N = 254, 244)-1.15 ± 1.51-0.81 ± 1.27
Week 3 (N = 252, 245)-1.55 ± 1.73-1.14 ± 1.45
Week 4 (N = 245, 229)-1.73 ± 1.80-1.30 ± 1.63
Week 5 (N = 241, 226)-1.87 ± 1.87-1.40 ± 1.68
Week 6 (N = 244, 227)-1.94 ± 1.95-1.46 ± 1.79
Week 7 (N = 240, 216)-2.01 ± 1.99-1.50 ± 1.78
Week 8 (N = 236, 212)-2.05 ± 2.00-1.52 ± 1.76
Week 9 (N = 232, 214)-2.09 ± 1.99-1.55 ± 1.86
Week 10 (N = 229, 212)-2.04 ± 2.11-1.55 ± 1.83
Week 11 (N = 230, 211)-2.09 ± 2.05-1.64 ± 1.79
Week 12 (N = 227, 209)-2.17 ± 2.06-1.68 ± 1.89
Week 13 (N = 225, 204)-2.19 ± 2.06-1.70 ± 1.90
Week 14 (N = 222, 208)-2.19 ± 2.16-1.79 ± 1.89
Week 15 (N = 196, 186)-2.13 ± 2.17-1.83 ± 1.87
Overall (N = 269, 262)-1.83 ± 1.93-1.37 ± 1.71
Statistical analysis
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0119 · Least square mean difference: -0.35 · 95% CI -0.62 to -0.08Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0135 · Least square mean difference: -0.34 · 95% CI -0.62 to -0.07Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0028 · Least square mean difference: -0.42 · 95% CI -0.69 to -0.14Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0016 · Least square mean difference: -0.44 · 95% CI -0.72 to -0.17Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0007 · Least square mean difference: -0.48 · 95% CI -0.75 to -0.20Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0006 · Least square mean difference: -0.48 · 95% CI -0.76 to -0.21Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0008 · Least square mean difference: -0.48 · 95% CI -0.75 to -0.20Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0003 · Least square mean difference: -0.52 · 95% CI -0.79 to -0.24Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0001 · Least square mean difference: -0.54 · 95% CI -0.82 to -0.26Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0005 · Least square mean difference: -0.49 · 95% CI -0.77 to -0.22Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0007 · Least square mean difference: -0.48 · 95% CI -0.76 to -0.20Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0001 · Least square mean difference: -0.54 · 95% CI -0.82 to -0.27Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.0001 · Least square mean difference: -0.56 · 95% CI -0.84 to -0.28Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0005 · Least square mean difference: -0.50 · 95% CI -0.78 to -0.22Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0031 · Least square mean difference: -0.43 · 95% CI -0.71 to -0.14Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0001 · Least square mean difference: -0.47 · 95% CI -0.71 to -0.23Analyzed for treatment, center, trauma type, week \& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.
SecondaryChange From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])

A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome.

Time frame:
Week 15
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])
units on a scalePregabalinPlacebo
Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])-2.40 ± 0.13-1.95 ± 0.13
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0050 · Least squares mean difference: -0.46 · 95% CI -0.77 to -0.14This secondary endpoint has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
SecondaryChange From Baseline in Pain Interference Index (BPI-sf)

BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. It consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes). The BPI-sf pain interference index was calculated as average of the seven individual pain interference scores.

Time frame:
Week 15
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pain Interference Index (BPI-sf)
units on a scalePregabalinPlacebo
Change From Baseline in Pain Interference Index (BPI-sf)-1.72 ± 0.13-1.33 ± 0.13
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0168 · Mean difference (final values): -0.38 · 95% CI -0.70 to -0.07This secondary endpoint has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
SecondaryChange From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores

A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale.

Time frame:
Week 15
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores
Units on a scalePregabalinPlacebo
Mobility-0.10 ± 0.03-0.09 ± 0.03
Self-care-0.08 ± 0.02-0.06 ± 0.02
Usual activities-0.12 ± 0.03-0.13 ± 0.04
Pain/Discomfort-0.35 ± 0.03-0.29 ± 0.04
Anxiety/Depression0.01 ± 0.03-0.02 ± 0.03
Dolan 1997 Index Score0.12 ± 0.010.11 ± 0.01
Dolan 2001 Index Score-0.13 ± 0.02-0.12 ± 0.02
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.6841 · Least squares mean difference: -0.01 · 95% CI -0.09 to 0.06This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.6564 · Least squares mean difference: -0.01 · 95% CI -0.07 to 0.04This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.8590 · Least squares mean difference: 0.01 · 95% CI -0.08 to 0.09This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.1628 · Least squares mean difference: -0.06 · 95% CI -0.14 to 0.02This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.4654 · Leaset squares mean difference: 0.03 · 95% CI -0.05 to 0.10This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.5000 · Least squares mean difference: 0.01 · 95% CI -0.02 to 0.04This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.5493 · Leaset squares mean difference: -0.02 · 95% CI -0.07 to 0.04This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
SecondaryBaseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.

MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.

Time frame:
Baseline
Reported as:
Median · Units on a scale
Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.
Units on a scalePregabalinPlacebo
Sleep Disturbance Score (N = 274, 265)42.50 ± 25.79143.75 ± 25.080
Sleep Adequancy Score (N = 274, 265)40.0 ± 28.15340.0 ± 28.582
Snoring Score (N = 272, 263)20.0 ± 33.48220.0 ± 34.084
Awaken Short of Breath Score (N = 274, 265)0.0 ± 25.6470.0 ± 21.541
Quantity of Sleep Score (hours) (N = 273, 265)6.0 ± 1.3606.0 ± 1.411
Somnolence Score (N = 274, 265)26.67 ± 21.61826.67 ± 19.884
Sleep Problem Index (9) Score (N = 274, 265)40.56 ± 20.28241.11 ± 19.720
Optimal Sleep Score (N = 273, 265)0.0 ± 0.4760.0 ± 0.487
SecondaryMean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.

MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.

Time frame:
Week 15
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.
Units on a scalePregabalinPlacebo
Sleep Disturbance Score (N = 257, 245)-14.71 (-17.57 to -11.85)-11.24 (-14.16 to -8.33)
Sleep Adequancy Score (N=257, 245)10.13 (6.49 to 13.76)8.16 (4.43 to 11.89)
Snoring Score (N = 257, 245)-2.22 (-5.46 to 1.03)-3.27 (-6.59 to 0.04)
Awaken Short of Breath Score (N = 257, 245)-3.61 (-6.30 to -0.92)-3.03 (-5.78 to -0.27)
Quantity of Sleep Score (hours) (N = 257, 245)0.42 (0.19 to 0.66)0.26 (0.03 to 0.50)
Somnolence Score (N = 257, 245)-1.61 (-3.99 to 0.77)-3.74 (-6.17 to -1.31)
Sleep Problem Index (9) Score (N = 257, 245)-9.86 (-12.17 to -7.56)-8.19 (-10.55 to -5.83)
Optimal Sleep Score (N = 256, 245)0.11 (0.05 to 0.18)0.04 (-0.03 to 0.10)
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0545 · Least square mean difference: 3.5 · 95% CI -0.07 to 7.00This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.3913 · Least square mean difference: -2.0 · 95% CI -6.47 to 2.54This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.6059 · Least square mean difference: -1.1 · 95% CI -5.06 to 2.96This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.7317 · Least square mean difference: 0.6 · 95% CI -2.76 to 3.93This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.2663 · Least square mean difference: -0.2 · 95% CI -0.45 to 0.12This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin · ANCOVA · p = 0.1562 · Least square mean difference: -2.1 · 95% CI -5.08 to 0.82This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.2490 · Least square mean difference: 1.7 · 95% CI -1.18 to 4.53This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
  • Pregabalin vs Placebo · ANCOVA · p = 0.0609 · Leaet squares mean difference: -0.1 · 95% CI -0.15 to 0.00This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.
SecondaryPercentage of Participants in MOS-SS With Optimal Sleep Status.

MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable.

Time frame:
Week 15
Reported as:
Number · Percentage of participants
Percentage of Participants in MOS-SS With Optimal Sleep Status.
Percentage of participantsPregabalinPlacebo
Any Improvements21.218.5
No Change66.160.8
Any Worsening6.213.2
Not applicable6.67.5
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.7165 (p-values based on CMH test stratified by pooled center and trauma type, patients with unknown status at baseline or endpoint will not be included in the calculation of p-values.)
SecondaryPercentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%.

Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.

Time frame:
Week 15
Reported as:
Number · Percentage of participants
Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%.
Percentage of participantsPregabalinPlacebo
Week 1 (N = 260, 258)11.925.04
Week 2 (N = 254, 244)27.1720.08
Week 3 (N = 252, 245)38.8930.20
Week 4 (N = 246, 229)41.8734.50
Week 5 (N = 241, 226)45.6438.05
Week 6 (N = 244, 227)48.7741.41
Week 7 (N = 240, 216)49.5843.06
Week 8 (N = 236, 213)50.4246.48
Week 9 (N = 232, 214)50.8647.66
Week 10 (N = 229, 212)52.8447.17
Week 11 (N = 231, 211)52.3851.18
Week 12 (N = 227, 209)54.6352.63
Week 13 (N = 226, 204)57.0854.41
Week 14 (N = 223, 208)57.4054.33
Week 15 (N = 196, 187)57.6558.29
Statistical analysis
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0028 · Odds ratio (or): 3.20 · 95% CI 1.50 to 6.86Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0360 · Odds ratio (or): 1.66 · 95% CI 1.03 to 2.68Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0235 · Odds ratio (or): 1.62 · 95% CI 1.07 to 2.45Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0619 · Odds ratio (or): 1.48 · 95% CI 0.98 to 2.24Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0677 · Odds ratio (or): 1.46 · 95% CI 0.97 to 2.20Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0707 · Odds ratio (or): 1.45 · 95% CI 0.97 to 2.16Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.1313 · Odds ratio (or): 1.37 · 95% CI 0.91 to 2.06Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.3072 · Odds ratio (or): 1.24 · 95% CI 0.82 to 1.86Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.3947 · Odds ratio (or): 1.19 · 95% CI 0.79 to 1.80Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.1462 · Odds ratio (or): 1.36 · 95% CI 0.90 to 2.05Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.6854 · Odds ratio (or): 1.09 · 95% CI 0.72 to 1.64Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.5025 · Odds ratio (or): 1.15 · 95% CI 0.76 to 1.74Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.4908 · Odds ratio (or): 1.16 · 95% CI 0.76 to 1.76Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.4245 · Odds ratio (or): 1.19 · 95% CI 0.78 to 1.80Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.8464 · Odds ratio (or): 0.96 · 95% CI 0.61 to 1.49Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
SecondaryPercentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50%

Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.

Time frame:
Week 15
Reported as:
Number · Percentage of participants
Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50%
Percentage of participantsPregabalinPlacebo
Week 1 (N = 260, 258)4.622.33
Week 2 (N = 254, 244)11.426.97
Week 3 (N = 252, 245)22.6213.47
Week 4 (N = 246, 229)25.2017.90
Week 5 (N = 241, 226)28.2219.47
Week 6 (N = 244, 227)29.5122.91
Week 7 (N= 240, 216)30.4222.22
Week 8 (N = 236, 213)33.0527.70
Week 9 (N = 232, 214)34.0526.17
Week 10 (N = 229, 212)32.7526.42
Week 11 (N = 231, 211)34.2025.59
Week 12 (N = 227, 209)37.8926.79
Week 13 (N = 226, 204)35.8427.45
Week 14 (N = 223, 208)37.6729.81
Week 15 (N = 196, 187)39.8034.22
Statistical analysis
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.1633 · Odds ratio (or): 2.11 · 95% CI 0.74 to 6.00Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0652 · Odds ratio (or): 1.92 · 95% CI 0.96 to 3.85Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0039 · Odds ratio (or): 2.20 · 95% CI 1.29 to 3.77Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0382 · Odds ratio (or): 1.71 · 95% CI 1.03 to 2.83Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0137 · Odds ratio (or): 1.86 · 95% CI 1.14 to 3.05Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0693 · Odds ratio (or): 1.55 · 95% CI 0.97 to 2.49Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0349 · Odds ratio (or): 1.68 · 95% CI 1.04 to 2.73Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.1227 · Odds ratio (or): 1.44 · 95% CI 0.91 to 2.29Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0364 · Odds ratio (or): 1.65 · 95% CI 1.03 to 2.63Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0667 · Odds ratio (or): 1.55 · 95% CI 0.97 to 2.49Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0176 · Odds ratio (or): 1.77 · 95% CI 1.10 to 2.84Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0030 · Odds ratio (or): 2.03 · 95% CI 1.27 to 3.23Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0256 · Odds ratio (or): 1.71 · 95% CI 1.07 to 2.74Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.0314 · Odds ratio (or): 1.66 · 95% CI 1.05 to 2.64Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.
  • Pregabalin vs Placebo · Gen linear model-logistic link function · p = 0.1889 · Odds ratio (or): 1.38 · 95% CI 0.85 to 2.21Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.

Adverse events

Collected over From Day -21 to Day 112 (week 16) i.e. from baseline until 1 day post last taper dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—2/274 (0.7%)75/274 (27.4%)
Placebo—7/265 (2.6%)33/265 (12.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPregabalinPlacebo
HaemorrhoidsGastrointestinal disorders0/2741/265
ConcussionInjury, poisoning and procedural complications0/2741/265
OverdoseInjury, poisoning and procedural complications0/2741/265
Post procedural dischargeInjury, poisoning and procedural complications0/2741/265
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/2741/265
Major depressionPsychiatric disorders0/2741/265
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2741/265
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/2741/265
Atrial fibrillationCardiac disorders1/2740/265
Urinary tract infectionInfections and infestations1/2740/265
Most frequent other events
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders40/27411/265
SomnolenceNervous system disorders27/2749/265
NauseaGastrointestinal disorders14/2748/265
FatigueGeneral disorders14/27410/265

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PregabalinPlaceboTotal
Mean52.8 ± 12.953.4 ± 12.753.1 ± 12.8
Age, Customized
Age, Customized(Participants)PregabalinPlaceboTotal
18 - 44 years5961120
45 - 64 years163154317
>=65 years5250102
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female132134266
Male142131273
08

Study locations

156 sites
  • Tennesse Valley Pain Consultants
    Huntsville, Alabama 35801, United States
  • Dedicated Clinical Research
    Goodyear, Arizona 85395, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • HOPE Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85027, United States
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • Quality of Life Medical & Research Centers, LLC
    Tucson, Arizona 85712, United States
  • Advanced Rx Clinical Research
    Artesia, California 90701, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • NervePro Medical Corp.
    Irvine, California 92618, United States
  • University of California, Irvine
    Irvine, California 92697, United States
  • Clinical and Translational Research Institute
    La Jolla, California 92093, United States
  • Alliance Research Centers
    Laguna Hills, California 92653, United States
  • South Orange County Surgical Medical Group
    Laguna Hills, California 92653, United States
  • Center For United Research, Inc.
    Lakewood, California 90805, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • USC I.D.S. Pharmacy
    Los Angeles, California 90089, United States
  • Samaritan Center for Medical Research
    Los Gatos, California 95032, United States
  • North County Clinical Research
    Oceanside, California 92056, United States
  • Allied Clinical Research
    Roseville, California 95661, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Elite Clinical Trials, Inc.
    Wildomar, California 92595, United States
  • Colorado Clinic
    Boulder, Colorado 80301, United States
  • Mountain View Clinical Research Inc.
    Denver, Colorado 80209, United States
  • St. Luke's Medical Clinic
    Fort Collins, Colorado 80525, United States
  • Investigational Drug Services, The George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • The George Washington University Medical Center (Department of Neurology)
    Washington, District of Columbia 20037, United States
  • The George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33472, United States
  • Advance Medical Research
    Clearwater, Florida 33756, United States
  • Innovative Research of West Florida
    Clearwater, Florida 33756, United States
  • Aga Clinical Trials
    Hialeah, Florida 33012, United States
  • Health Care Family Rehab & Research Center
    Hialeah, Florida 33012, United States
  • Research in Miami, Inc.
    Hialeah, Florida 33013, United States
  • Homestead Medical Research , Inc.
    Homestead, Florida 33030, United States
  • AMPM Research Clinic
    Miami Gardens, Florida 33169, United States
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33015, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33136, United States
  • Florida International Research Center
    Miami, Florida 33173, United States
  • Kendall South Medical Center, Inc.
    Miami, Florida 33185, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • A-One Family Practice
    Ormond Beach, Florida 32174, United States
  • Aba Family Medicine, LLC
    Ormond Beach, Florida 32174, United States
  • Ribo Research, LLC dba Peninsula Resarch
    Ormond Beach, Florida 32174, United States
  • Comprehensive Pain Care of South Florida
    Royal Palm Beach, Florida 33411, United States
  • Sarasota Pain Medicine Research
    Sarasota, Florida 34238, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Georgia Institute for Clinical Research, LLC
    Marietta, Georgia 30060, United States
  • Advanced Internal Medicine, PC
    Stockbridge, Georgia 30281, United States
  • Research 1 Clinical Research Network, Inc. (Administrative Office Only)
    Stockbridge, Georgia 30281, United States
  • Rehabilitation Institute of Chicago
    Chicago, Illinois 60611, United States
  • Chicago Anesthesia Associates
    Chicago, Illinois 60657, United States
  • Kansas City Bone & Joint Clinic
    Overland Park, Kansas 66211, United States
  • Otri-Med Corporation
    Edgewood, Kentucky 41017, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Centex Studies, Inc
    Lake Charles, Louisiana 70601, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Medex Healthcare Research, Inc.
    Saint Louis, Missouri 63117, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Heartland Clinical Research, Inc.
    Omaha, Nebraska 68134, United States
  • Advanced Biomedical Research of America
    Las Vegas, Nevada 89123, United States
  • University of Rochester, Translational Pain Research
    Rochester, New York 14618, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28209, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Northern Ohio Neurosciences, LLC
    Bellevue, Ohio 44811, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • Northwest Ohio Research Center, LLC
    Toledo, Ohio 43623, United States
  • Robert L Kalb, M.D, Inc
    Toledo, Ohio 43623, United States
  • Cor Clinical Research, Llc
    Oklahoma City, Oklahoma 73103, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network, Inc.
    Portland, Oregon 97210, United States
  • Allegheny Pain Management, P.C.
    Altoona, Pennsylvania 16602, United States
  • CRI Lifetree
    Philadelphia, Pennsylvania 19139, United States
  • Pharmacorp Clinical Trials, Inc.
    Charleston, South Carolina 29412, United States
  • TLM Medical Services, LLC
    Columbia, South Carolina 29204, United States
  • Piedmont Comprehensive Pain Management Group, LLC
    Greenville, South Carolina 29601, United States
  • Pharmacum Biomedical Research
    Greenville, South Carolina 29605, United States
  • New Phase Research and Development
    Knoxville, Tennessee 37919, United States
  • Dallas Pain Consultants
    Dallas, Texas 75203, United States
  • FutureSearch Trials of Dallas, L. P.
    Dallas, Texas 75231, United States
  • Abigail R. Neiman, MD, PA
    Houston, Texas 77024, United States
  • Agadadash Kuliev, MD, PA
    Houston, Texas 77043, United States
  • Biopharma Informatic Inc. Research Center
    Houston, Texas 77043, United States
  • Medstar Clinical Research Associates
    Houston, Texas 77083, United States
  • ClinRx Research, LLC
    Richardson, Texas 75080, United States
  • DCT - Stone Oak, LLC dba Discovery Clinical Trials
    San Antonio, Texas 78258, United States
  • Sealy Urgent Care Center and Medical Clinic
    Sealy, Texas 77474, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • J. Lewis Research, Inc./Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewish Research, Inc./Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Integrated Neurology Services , PLLC
    Arlington, Virginia 22205, United States
  • IntegraTrials, LLC
    Arlington, Virginia 22205, United States
  • Washington Center for Pain Management LLC
    Bellevue, Washington 98004, United States

Showing the first 100 of 156 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Markman J, Resnick M, Greenberg S, Katz N, Yang R, Scavone J, Whalen E, Gregorian G, Parsons B, Knapp L. Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. J Neurol. 2018 Dec;265(12):2815-2824. doi: 10.1007/s00415-018-9063-9. Epub 2018 Sep 21. PubMed 30242745 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2012
First posted
Oct 5, 2012
Start
Oct 2012
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jun 7, 2017
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01701362
Responsible party
Sponsor
First posted
Oct 5, 2012
Start date
Oct 2012
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jun 7, 2017
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion